RLYB News and Press, Rallybio Corporation From 09/15/23

2023-09-15 17:15:40 ET Summary Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C...

-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants -- -- Mean Estimated Elimination Half-Life for RLYB116 was > 30...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: ...

2023-08-08 10:19:41 ET Rallybio press release ( NASDAQ: RLYB ): Q2 GAAP EPS of -$0.46. As of June 30, 2023, cash, cash equivalents and marketable securities were $137.8 million. For further details see: Rallybio GAAP EPS of -$0.46

-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 -- -- RLYB212 Phase 1 Multiple Dose Cohort Study Results Expected in 4Q 2023 -- -- Initial Data from RLYB116 Phase ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will partici...

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29 th International Complement Workshop (ICW), which will take place in ...

2023-07-07 17:29:48 ET Gainers: Black Diamond Therapeutics ( NASDAQ: BDTX ) +9% . CareMax ( CMAX ) +5% . Outbrain  ( OB ) +5% . Sientra ( SIEN ) +4% . iHeartMedia ( IHRT ) +4% . Losers: CRISPR Therapeutics ( CR...

2023-06-29 07:22:15 ET Rallybio ( NASDAQ: RLYB ) COO, President and Co-Founder Stephen Uden, M.D. will take additional responsibility of CEO, effective August 1, 2023. Dr. Uden’s will succeed Martin Mackay, who will assume the role of Executive Chairman. T...

-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patient...